WO2022239068A1 - Inhibiteur d'orage cytokinique - Google Patents

Inhibiteur d'orage cytokinique Download PDF

Info

Publication number
WO2022239068A1
WO2022239068A1 PCT/JP2021/017721 JP2021017721W WO2022239068A1 WO 2022239068 A1 WO2022239068 A1 WO 2022239068A1 JP 2021017721 W JP2021017721 W JP 2021017721W WO 2022239068 A1 WO2022239068 A1 WO 2022239068A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluorophenyl
pyrazin
ylamino
ethylamino
ethyl
Prior art date
Application number
PCT/JP2021/017721
Other languages
English (en)
Japanese (ja)
Inventor
勇太 大谷
歩美 本田
Original Assignee
日本新薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日本新薬株式会社 filed Critical 日本新薬株式会社
Priority to PCT/JP2021/017721 priority Critical patent/WO2022239068A1/fr
Publication of WO2022239068A1 publication Critical patent/WO2022239068A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Cycloalkyl includes, for example, those having 3 to 8 carbon atoms, specifically cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
  • alkoxyalkyl examples include the same as the above-mentioned "alkoxy”.
  • saturated cyclic amino group includes, for example, a 4- to 7-membered saturated cyclic amino group having one or two N, optionally having one O or S as a ring-constituting atom, specifically include 1-azetidinyl, 1-pyrrolidinyl, 1-imidazolidinyl, piperidino, 1-piperazinyl, 1-tetrahydropyrimidinyl, morpholino, thiomorpholino, 1-homopiperazinyl.
  • thiazolyl e.g. 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiadiazolyl, isothiazolyl ( 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), pyridyl (e.g. 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g. 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (e.g. 2 -pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrazinyl (eg 2-pyrazinyl).
  • pyridyl e.g. 2-pyridyl, 3-pyridyl, 4-pyridyl
  • pyridazinyl e.g. 3-pyridazinyl, 4-pyridazinyl
  • pyrimidinyl e
  • Palladium catalyst ligands that can be used include, for example, 1,1′-bis(diphenylphosphino)ferrocene, 4,5-bis(diphenylphosphino)-9,9′-dimethylxanthene, 2-dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl, ( ⁇ )-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 2-(di-t-butylphosphino)biphenyl, bis Mention may be made of [2-(diphenylphosphino)phenyl]ether, tri-t-butylphosphine.
  • Palladium catalysts include, for example, tris(dibenzylideneacetone)(chloroform)dipalladium(0), tris(dibenzylideneacetone)dipalladium(0), and palladium(II) acetate.
  • the amount of palladium catalyst that can be used is suitably in the range of 0.001 to 0.1 mol per 1 mol of the aryl halide.
  • Process 1 Compound [18] can be produced by reacting compound [16] and alcohol compound [17] in a suitable solvent in the presence of a base at -20°C to 100°C.
  • Usable bases include, for example, sodium hydride and sodium hydroxide.
  • Solvents that can be used are not particularly limited as long as they do not participate in the reaction. Examples include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane and tetrahydrofuran, N,N-dimethylformamide, N, Amides such as N-dimethylacetamide and N-methyl-2-pyrrolidone, water, and mixed solvents thereof can be used.
  • the reaction time varies depending on the type of raw materials used and the reaction temperature, but is generally 30 minutes to 24 hours.
  • Palladium catalysts that can be used include, for example, tris(dibenzylideneacetone)(chloroform)dipalladium(0), tris(dibenzylideneacetone)dipalladium(0), and palladium(II) acetate.
  • the amount of palladium catalyst that can be used is suitably in the range of 0.001 to 0.1 mol per 1 mol of the aryl halide.
  • Palladium catalyst ligands that can be used include, for example, 4,5-bis(diphenylphosphino)-9,9′-dimethylxanthene, ( ⁇ )-2,2′-bis(diphenylphosphino)-1,1 '-Binaphthyl, 2-(di-t-butylphosphino)biphenyl, bis[2-(diphenylphosphino)phenyl]ether, tri-t-butylphosphine can be mentioned.
  • Usable bases include, for example, sodium t-butoxide, tripotassium phosphate, and cesium carbonate.
  • the reaction time varies depending on the type of raw material used, the reaction temperature, etc., but is usually within the range of 10 minutes to 24 hours.
  • R 8 is a group represented by the following general formula [9], (Wherein, R M , R N , R O , * are as defined above.), or even substituted with 1 or 2 groups selected from the group consisting of cyano, halogen, hydroxy, alkoxy, alkylcarbonyl, carbamoyl, alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, hydroxycarbonyl and alkoxyalkyl It represents good heteroaryl (limited to those in which the bond is from C). )
  • This reaction is a cross-coupling reaction using compound [1a] and organoboron compound [20], and can be carried out by a method known per se.
  • This reaction can be carried out, for example, in the presence of a palladium catalyst and a base in a suitable solvent at 20-200°C.
  • Palladium catalysts that may be used include, for example, tetrakis(triphenylphosphine)palladium, dichlorobis(triphenylphosphine)palladium, 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride-dichloromethane complexes. can be done.
  • This reaction is a condensation reaction of compound [21] and compound [13] using a palladium catalyst, and is carried out by a method known per se.
  • Solvents that can be used are not particularly limited as long as they do not participate in the reaction. Examples include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane and tetrahydrofuran, N,N-dimethylformamide, N,N -dimethylacetamide, amides such as N-methyl-2-pyrrolidone, or mixed solvents thereof.
  • This reaction can be carried out in the presence of a base within the range of 20°C to 200°C.
  • Palladium catalysts that may be used include, for example, tris(dibenzylideneacetone)(chloroform)dipalladium(0), tris(dibenzylideneacetone)dipalladium(0), palladium(II) acetate.
  • the amount of palladium catalyst that can be used is suitably in the range of 0.001 to 0.1 mol per 1 mol of the aryl halide.
  • Palladium catalyst ligands that can be used include, for example, 1,1′-bis(diphenylphosphino)ferrocene, 4,5-bis(diphenylphosphino)-9,9′-dimethylxanthene, 2-dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl, ( ⁇ )-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 2-(di-t-butylphosphino)biphenyl, bis Mention may be made of [2-(diphenylphosphino)phenyl]ether, tri-t-butylphosphine.
  • Usable bases include, for example, sodium t-butoxide, tripotassium phosphate, and cesium carbonate.
  • the reaction time varies depending on the type of raw material used, the reaction temperature, etc., but is usually within the range of 10 minutes to 24 hours.
  • Compound [21] which is a raw material compound, can be produced, for example, according to the following three methods.
  • This reaction is a cross-coupling reaction using compound [22] and organoboron compound [20], and can be carried out by a method known per se.
  • This reaction can be carried out, for example, in the presence of a palladium catalyst and a base in a suitable solvent at 20 to 200°C.
  • Palladium catalysts that may be used include, for example, tetrakis(triphenylphosphine)palladium, dichlorobis(triphenylphosphine)palladium, 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride-dichloromethane complexes. can be done.
  • Palladium catalysts that can be used include, for example, tris(dibenzylideneacetone)(chloroform)dipalladium(0), tris(dibenzylideneacetone)dipalladium(0), and palladium(II) acetate.
  • the amount of palladium catalyst that can be used is suitably in the range of 0.001 to 0.1 mol per 1 mol of the aryl halide.
  • This reaction is a condensation reaction of compound [26] and compound [13] using a palladium catalyst, and can be carried out by a method known per se.
  • Solvents that can be used are not particularly limited as long as they do not participate in the reaction. Examples include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane and tetrahydrofuran, N,N-dimethylformamide, N, Amides such as N-dimethylacetamide and N-methyl-2-pyrrolidone, or mixed solvents thereof can be used.
  • This reaction can be carried out in the presence of a base within the range of 20°C to 200°C.
  • Palladium catalyst ligands that can be used include, for example, 1,1′-bis(diphenylphosphino)ferrocene, 4,5-bis(diphenylphosphino)-9,9′-dimethylxanthene, 2-dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl, ( ⁇ )-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 2-(di-t-butylphosphino)biphenyl, bis Mention may be made of [2-(diphenylphosphino)phenyl]ether, tri-t-butylphosphine.
  • Usable bases include, for example, sodium t-butoxide, tripotassium phosphate, and cesium carbonate.
  • the reaction time varies depending on the type of raw material used, the reaction temperature, etc., but is usually within the range of 10 minutes to 24 hours.
  • Compound [26] which is a starting compound, can be produced, for example, according to the following two methods. (X 1 , R 1 , R 12 , Hal 1 and Hal 2 are as defined above.)
  • a Compound [26] can be produced by reacting compound [12] and compound [25] in a suitable solvent in the presence of a base at 20°C to 200°C.
  • bases include, for example, pyridine, triethylamine, N,N-diisopropylethylamine, potassium carbonate and sodium hydrogen carbonate.
  • Palladium catalyst ligands that can be used include, for example, 1,1′-bis(diphenylphosphino)ferrocene, 4,5-bis(diphenylphosphino)-9,9′-dimethylxanthene, 2-dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl, ( ⁇ )-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 2-(di-t-butylphosphino)biphenyl, bis Mention may be made of [2-(diphenylphosphino)phenyl]ether, tri-t-butylphosphine.
  • Usable bases include, for example, sodium t-butoxide, tripotassium phosphate, and cesium carbonate.
  • the reaction time varies depending on the type of raw material used, the reaction temperature, etc., but is usually within the range of 10 minutes to 24 hours.
  • R 2 is 1 or 2 groups selected from the group consisting of cyano, halogen, hydroxy, alkoxy, alkylcarbonyl, carbamoyl, alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, hydroxycarbonyl and alkoxyalkyl
  • X 1 , R 1 , R 5 and Hal 1 are as defined above.
  • R 13 is cyano, halogen, hydroxy, alkoxy, alkylcarbonyl, carbamoyl, alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, heteroaryl optionally substituted with 1 or 2 groups selected from the group consisting of hydroxycarbonyl and alkoxyalkyl (limited to those with a bond extending from N);
  • the starting compound, compound [27] can be produced according to the following method.
  • This reaction is a cross-coupling reaction using compound [12] and compound [28], and can be carried out by a method known per se.
  • This reaction can be carried out, for example, in the presence or absence of a copper catalyst in a suitable solvent at 20 to 200°C.
  • a copper catalyst examples include copper iodide and copper acetate.
  • the amount of copper catalyst that can be used is suitably within the range of 0.01 to 0.2 mol per 1 mol of the aryl halide.
  • examples of copper ligands include trans-N,N'-dimethylcyclohexane-1,2-diamine, trans-1,2-cyclohexanediamine, 1,10-phenanthroline, and the like.
  • Usable reaction solvents are not particularly limited as long as they do not participate in the reaction. Examples include ethers such as tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane; Examples include amides such as N-dimethylformamide and N,N-dimethylacetamide, hydrocarbons such as benzene and toluene, and mixed solvents thereof. Usable bases include, for example, tripotassium phosphate, potassium carbonate, sodium carbonate, cesium carbonate and the like.
  • the reaction time varies depending on the type of raw material used and the reaction temperature, but is usually within the range of 30 minutes to 24 hours.
  • R 2 is alkoxycarbonyl (X 1 , R 1 , R 5 and Hal 1 are as defined above.
  • R 14 represents alkyl.
  • This reaction is a condensation reaction of compound [30] and compound [19] using a palladium catalyst, and can be carried out in the same manner as in step 2 of the method for producing compound [15], which is the raw material compound.
  • This reaction is a hydrolysis reaction of compound [1f] and can be carried out by a method known per se.
  • compound [1g] can be produced by hydrolyzing compound [1f] in the presence of an acid or base.
  • the acid used in this reaction include inorganic acids such as hydrochloric acid and sulfuric acid
  • examples of the base include inorganic bases such as sodium hydroxide and potassium hydroxide.
  • the reaction solvent that can be used in this reaction include alcohols such as methanol and ethanol, ethers such as tetrahydrofuran and 1,4-dioxane, water, and mixed solvents thereof.
  • the reaction temperature is 0° C. to 100° C., and the reaction time is usually 30 minutes to 24 hours.
  • R 2 is (a) a saturated cyclic amino group optionally substituted with alkyl or alkylsulfonyl, or (b) alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, haloalkyl, dialkylaminoalkyl, alkoxyalkyl , and aminocarbonyl optionally substituted with 1 or 2 groups selected from the group consisting of hydroxyalkyl (X 1 , R 1 and R 5 are as defined above.
  • R 15 and R 16 are the same or different and are H, alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, haloalkyl, dialkylaminoalkyl, represents alkoxyalkyl or hydroxyalkyl, or together with adjacent N represents a saturated cyclic amino group. Such saturated cyclic amino group may be substituted with alkyl or alkylsulfonyl.
  • This reaction is a condensation reaction between compound [1g] and compound [31], and can be carried out by a method known per se as a condensation reaction.
  • Compound [1h] can be synthesized by reacting a carboxylic acid represented by compound [1g] or a reactive derivative thereof with compound [31].
  • Examples of reactive derivatives of compound [1g] include those commonly used in amide condensation formation reactions, such as acid halides (e.g., acid chlorides, acid bromides), mixed acid anhydrides, imidazolides, and active amides. .
  • the reaction can be carried out at -20 to 100°C using a condensing agent in the presence or absence of a base.
  • Condensing agents that can be used in this reaction include, for example, 1,1′-oxalyldiimidazole, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, dicyclohexylcarbodiimide, diethyl cyanophosphonate, O-(benzotriazole -1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate.
  • Additives that can be used include, for example, 1-hydroxybenzotriazole and 1-hydroxy-7-azabenzotriazole.
  • the reaction time varies depending on the type of raw material used, the reaction temperature, etc., but is usually within the range of 10 minutes to 24 hours.
  • the amount of the compound [31] and the condensing agent to be used is, for example, in the range of 1 to 3 mol per 1 mol of the compound [1g].
  • R 2 is H, alkylcarbonyl, saturated heterocyclic group containing 1 N optionally substituted with alkylsulfonyl, or alkyl optionally substituted with hydroxy or alkoxy
  • X 1 , R 1 , R 5 and Hal 1 are as defined above.
  • R 17 is a saturated heterocyclic group containing one N optionally substituted with H, alkylcarbonyl, alkylsulfonyl, or represents alkyl optionally substituted with hydroxy or alkoxy
  • This reaction is a condensation reaction of compound [32] and compound [13] using a palladium catalyst, and can be carried out in the same manner as in production method 1 above.
  • the amount of palladium catalyst that can be used is suitably in the range of 0.001 to 0.1 mol per 1 mol of the aryl halide.
  • 4,5-bis(diphenylphosphino)-9,9'-dimethylxanthene, 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, 2-dicyclohexyl as ligands for palladium if necessary Phosphino-2',6'-dimethoxybiphenyl and the like can be used.
  • Usable cyano compounds include copper (I) cyanide, zinc (II) cyanide, potassium cyanide, and sodium cyanide.
  • Usable reaction solvents are not particularly limited as long as they do not participate in the reaction. Examples include ethers such as tetrahydrofuran and 1,4-dioxane, alcohols such as methanol and ethanol, N,N-dimethylformamide, N, Examples include amides such as N-dimethylacetamide and N-methyl-2-pyrrolidone, hydrocarbons such as benzene and toluene, dimethylsulfoxide, water, and mixed solvents thereof.
  • the reaction time varies depending on the type of raw material used and the reaction temperature, but is usually within the range of 30 minutes to 24 hours.
  • This reaction is a condensation reaction of compound [33] and compound [13] using a palladium catalyst, and can be carried out in the same manner as in Production Method 4-2 above.
  • Compound [33] which is a starting compound, can be produced according to the following method. (R 1 , R 18 , Hal 1 and Hal 3 are as defined above.)
  • This reaction is a condensation reaction of compound [34] and compound [19] using a palladium catalyst, and can be carried out in the same manner as in step 2 of method A in production method 3-2 above.
  • This reaction is a hydrolysis reaction of compound [1k] and can be carried out in the same manner as in Production Method 7 above.
  • R A is a group represented by the following general formula [35] (Wherein, * is as defined above.
  • R 19 and R 20 are the same or different and represent H, alkyl, cycloalkyl, (cycloalkyl)alkyl or alkoxyalkyl, or adjacent N together with represents a saturated cyclic amino group.)
  • This reaction is a condensation reaction between compound [1j] and compound [36], and can be carried out in the same manner as in production method 8 above.
  • R 4 is alkyl (X, R 1 , R 2 , R 3 , R 5 and Hal 1 are as defined above.
  • R 21 represents alkyl.
  • This reaction is a condensation reaction of compound [37] and compound [13] using a palladium catalyst, and can be carried out in the same manner as in Production Method 4-2 above.
  • Compound [37] which is a starting compound, can be produced according to the following method. (X 1 , R 1 , R 2 , R 21 and Hal 1 are as defined above. Hal 4 represents halogen.)
  • This step can be produced by reacting compound [38] and compound [39] in an appropriate solvent in the presence of a base at 20°C to 200°C using a microwave if necessary.
  • Usable bases include, for example, sodium hydride, lithium diisopropylamide, n-butyllithium and the like.
  • Solvents that can be used are not particularly limited as long as they do not participate in the reaction. Hydrocarbons such as benzene and toluene, acetonitrile, or mixed solvents thereof can be mentioned.
  • the reaction time varies depending on the type of raw materials used and the reaction temperature, but is usually within the range of 10 minutes to 24 hours.
  • This reaction is a condensation reaction of compound [40] and compound [13] using a palladium catalyst, and can be carried out in the same manner as in production method 1 above.
  • Sodium t-butoxide is suitable as a base that can be used in this reaction.
  • Compound [40] which is a starting compound, can be produced according to the following method. (X 1 , R 1 , R 2 , Hal 1 and Hal 3 are as defined above.)
  • Process 1 Compound [42] can be produced according to known methods (J.Org.Chem., 65, 2000, 9059-9068, etc.).
  • This step is a condensation reaction of compound [42] and compound [43] using a palladium catalyst, and can be carried out, for example, by the same method as in Production Method 1 above.
  • the compound of the present invention can be used as a medicine as it is, it can also be used in the form of a pharmaceutically acceptable salt by a known method.
  • Such salts include salts of mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid, Examples include salts of organic acids such as methanesulfonic acid.
  • the hydrochloride of the compound of the present invention can be obtained by dissolving the compound of the present invention in an alcohol solution, ethyl acetate solution or diethyl ether solution of hydrogen chloride.
  • optical isomers are known, for example, from the racemate obtained as described above using an optically active acid (tartaric acid, dibenzoyltartaric acid, mandelic acid, 10-camphorsulfonic acid, etc.) by utilizing its basicity. or optically active compounds prepared in advance can be used as starting materials. In addition, it can also be produced by optical resolution using a chiral column or by asymmetric synthesis.
  • an optically active acid tartaric acid, dibenzoyltartaric acid, mandelic acid, 10-camphorsulfonic acid, etc.
  • the compound of the present invention has geometric isomers or tautomers, not only any one of the isomers but also a mixture thereof is included in the compound of the present invention.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof has STAT3 inhibitory activity and/or IL-17 production inhibitory activity, as shown in the test examples below, and is useful as a pharmaceutical.
  • compositions containing the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient include, for example, cytokine storm/cytokine release syndrome (CRS), respiratory disorders, psoriasis, Crohn's disease, It can be used as a prophylactic or therapeutic agent for ulcerative colitis, ankylosing myelitis, axial spinal arthritis, palmoplantar pustulosis, hidradenitis suppurativa, lupus nephritis, systemic lupus erythematosus, polymyositis/dermatomyositis. .
  • CRS cytokine storm/cytokine release syndrome
  • respiratory disorders psoriasis
  • Crohn's disease It can be used as a prophylactic or therapeutic agent for ulcerative colitis, ankylosing myelitis, axial spinal arthritis, palmoplantar pustulosis, hidradenitis suppurativa, lupus neph
  • a pharmaceutical composition containing the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient is, for example, a prophylactic or therapeutic agent for cytokine storm/cytokine release syndrome (CRS) or respiratory disorders.
  • CRS cytokine storm/cytokine release syndrome
  • respiratory disorders can be used as a prophylactic or therapeutic agent for cytokine storm/cytokine release syndrome (CRS) or respiratory disorders.
  • cytokine storm/cytokine release syndrome is, for example, cytokine storm/cytokine release syndrome (CRS) associated with viral infections, preferably influenza virus, novel influenza virus, coronavirus (e.g., SARS-CoV, MERS-CoV, etc.), or cytokine storm/cytokine release syndrome (CRS) due to novel coronavirus, more preferably cytokine storm/cytokine release due to SARS-CoV-2 (or COVID-19) syndrome (CRS).
  • CRS cytokine storm/cytokine release syndrome
  • the respiratory disorder is, for example, pneumonia or acute respiratory distress syndrome associated with a viral infection, preferably influenza virus, pandemic influenza virus, coronavirus (e.g., SARS-CoV, MERS- CoV, etc.), or pneumonia or acute respiratory distress syndrome associated with viral infections caused by the novel coronavirus, more preferably pneumonia (especially severe pneumonia) caused by SARS-CoV-2 (or COVID-19).
  • a viral infection preferably influenza virus, pandemic influenza virus, coronavirus (e.g., SARS-CoV, MERS- CoV, etc.), or pneumonia or acute respiratory distress syndrome associated with viral infections caused by the novel coronavirus, more preferably pneumonia (especially severe pneumonia) caused by SARS-CoV-2 (or COVID-19).
  • compositions containing the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient are, for example, COVID-19 patients, preferably COVID-19 patients, and L- This is a pharmaceutical composition for administration to a patient with enhanced 17 production.
  • a pharmaceutical composition containing the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient can be It can be used as a prophylactic or therapeutic agent for arthritis, palmoplantar pustulosis, hidradenitis suppurativa, lupus nephritis, systemic lupus erythematosus, polymyositis/dermatomyositis.
  • a pharmaceutical composition containing the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient is a pharmaceutical composition for administration to patients with enhanced L-17 production.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof has STAT3 inhibitory activity and/or IL-17 production inhibitory activity, and is useful as a cytokine storm inhibitor.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof has IL-17 production inhibitory activity and is useful as an IL-17 production inhibitor.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof has STAT3 inhibitory activity and is useful as a STAT3 inhibitory agent.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof when administering the compound of the present invention or a pharmaceutically acceptable salt thereof as a medicament, the compound of the present invention or a pharmaceutically acceptable salt thereof as such or in a pharmaceutically acceptable non-toxic and inert carrier, for example, It is administered to mammals, including humans, as a pharmaceutical composition containing 0.001% to 99.5%, preferably 0.1% to 90%.
  • compositions of the present invention are preferably administered in dosage unit form.
  • the pharmaceutical composition can be administered intratissueally, orally, intravenously, locally (percutaneously, eye drops, etc.), or rectally. Of course, it is administered in dosage forms suitable for these administration methods.
  • the compounds of Examples 1 to 234 were synthesized with reference to the descriptions in WO2010/090290 and WO2012/005299. Structural formulas of the compounds of Examples 1 to 234 are shown in Tables 1 to 12.
  • Test Example 1 STAT3 phosphorylation inhibitory action on mouse blood cells 1.
  • Administration of test substance to mice and blood collection Compound A was orally administered to mice (BALB/cA Jcl, 7 weeks old, male) at 10, 25 and 50 mg/kg. 0.5% methylcellulose was orally administered to the vehicle group. Blood was collected from the posterior vena cava under isoflurane inhalation anesthesia before administration and 1 and 3 hours after administration. Three mice were used in each group.
  • pSTAT3 production 150 ⁇ L of blood was taken and washed twice with phosphate buffer. Thereafter, pSTAT3 was measured according to the procedure of the ELISA kit (phosphoELISA kit STAT3 [pY705], Invitrogen cat#KHO0481).
  • Test Example 2 IL-17 production inhibitory action 1.
  • DMSO Dimethylsulfoxide
  • RPMI Roswell Park Memorial Institute
  • FBS fetal bovine serum
  • Peripheral blood mononuclear cells were suspended at 0.56 ⁇ 10 6 cells/mL in RPMI-1640 medium containing 10% FBS, and each 90 ⁇ L (0.5 ⁇ 10 5 cells) was placed in a 96-well plate (Corning, 353075). sown in Immediately after seeding, 10 ⁇ L of the test substance solution was added and cultured in a 5% carbon dioxide (CO2), 37°C incubator. During culture, Dynabeads (registered trademark) Human T-Activator CD3/CD28 for T Cell Expansion and Activation (Thermo Fisher Scientific, 11161D) was added at a ratio of 0.88 ⁇ L per 10 ⁇ L of RPMI-1640 medium containing 10% FBS. mixed with.
  • CO2 carbon dioxide
  • Formulation example 1 Tablet (oral tablet) 5.0 mg of the compound of the present invention of Example 1 in 80 mg of one prescription tablet Corn starch 46.6 mg Crystalline cellulose 24.0 mg Methyl cellulose 4.0 mg Magnesium stearate 0.4 mg The mixed powder of this ratio is tableted by a conventional method to give tablets for oral use.
  • Formulation example 2 Tablet (oral tablet) 5.0 mg of the compound of the present invention of Example 2 in 80 mg of one prescription tablet Corn starch 46.6 mg Crystalline cellulose 24.0mg Methyl cellulose 4.0 mg Magnesium stearate 0.4 mg The mixed powder of this ratio is tableted by a usual method to give an oral tablet.
  • compositions that treat, for example, cytokine storm/cytokine release syndrome (CRS), psoriasis, Crohn's disease, ulcerative colitis, ankylosing myelitis, axial spinal arthritis, palmoplantar pustulosis, hidradenitis suppurativa, lupus It can be used as a prophylactic or therapeutic agent for nephritis, systemic lupus erythematosus, or polymyositis/dermatomyositis.
  • CRS cytokine storm/cytokine release syndrome
  • psoriasis Crohn's disease
  • ulcerative colitis ankylosing myelitis
  • axial spinal arthritis palmoplantar pustulosis
  • hidradenitis suppurativa lupus It can be used as a prophylactic or therapeutic agent for nephritis, systemic lupus erythematosus, or polymyositis/derma

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne un nouvel inhibiteur d'orage cytokinique contenant, en tant que principe actif, un composé représenté par la formule générale [1] : [Dans la formule, R1 R2, R3, R4, R5 et X sont tels que définis dans la description], ou un sel pharmacologiquement acceptable de celui-ci.
PCT/JP2021/017721 2021-05-10 2021-05-10 Inhibiteur d'orage cytokinique WO2022239068A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2021/017721 WO2022239068A1 (fr) 2021-05-10 2021-05-10 Inhibiteur d'orage cytokinique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2021/017721 WO2022239068A1 (fr) 2021-05-10 2021-05-10 Inhibiteur d'orage cytokinique

Publications (1)

Publication Number Publication Date
WO2022239068A1 true WO2022239068A1 (fr) 2022-11-17

Family

ID=84028503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/017721 WO2022239068A1 (fr) 2021-05-10 2021-05-10 Inhibiteur d'orage cytokinique

Country Status (1)

Country Link
WO (1) WO2022239068A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019065793A1 (fr) * 2017-09-28 2019-04-04 日本新薬株式会社 Cristaux

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019065793A1 (fr) * 2017-09-28 2019-04-04 日本新薬株式会社 Cristaux

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOJYO SHINTARO, UCHIDA MONA, TANAKA KUMIKO, HASEBE RIE, TANAKA YUKI, MURAKAMI MASAAKI, HIRANO TOSHIO: "How COVID-19 induces cytokine storm with high mortality", INFLAMMATION AND REGENERATION, vol. 40, no. 1, 1 December 2020 (2020-12-01), XP093007563, DOI: 10.1186/s41232-020-00146-3 *
HONDA AYUMI, KURAMOTO KAZUYA, NIWA TOMOKO, NAITO HARUNA: "NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways", BLOOD CANCER JOURNAL, vol. 8, no. 7, 1 July 2018 (2018-07-01), pages 62, XP093007556, DOI: 10.1038/s41408-018-0098-z *
KODAMA, A. ET AL.: "P-257: Ns-018 suppresses myeloma cell proliferation and osteolysis by inhibiting JAK2 and SRC signaling. ", CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA, vol. 13, no. 1, 31 January 2013 (2013-01-31), NL , pages S167 - S168, XP009541272, ISSN: 2152-2650 *
KURAMOTO KAZUYA; KODAMA AYUMI; HOMAN JUNKO; NAKAYA YOHEI; KITAMURA TOSHIO; NAITO HARUNA: "Dual Inhibition of the STAT3 and Src Pathways by NS-018, a JAK2 and Src-Family Kinase Inhibitor, Reduces Myeloma Cell Proliferation and Adhesion and Suppresses Osteoclast Formation", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 118, no. 21, 18 November 2011 (2011-11-18), US , pages 2900, XP086625506, ISSN: 0006-4971, DOI: 10.1182/blood.V118.21.2900.2900 *

Similar Documents

Publication Publication Date Title
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
RU2535217C2 (ru) Производные аминопиразина и лекарственные средства
US20130216498A1 (en) Imidazopyridine derivatives as jak inhibitors
WO2012020786A1 (fr) Composition pharmaceutique
MX2014008647A (es) Compuesto de pirazin-carboxamida.
JP5668756B2 (ja) 悪性リンパ腫治療剤
WO2012005299A1 (fr) Inhibiteur de ros de tyrosine kinase
WO2022239068A1 (fr) Inhibiteur d'orage cytokinique
WO2023175932A1 (fr) Agent thérapeutique pour myélofibrose à haut risque
JP2022548230A (ja) 新規化合物及び方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21941802

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21941802

Country of ref document: EP

Kind code of ref document: A1